Download Guided Lecture Notes, Chapter 37, Thyroid and Parathyroid Agents

Guided Lecture Notes, Chapter 37, Thyroid and Parathyroid Agents
Learning Objective 1: Explain the control of the synthesis and secretion of thyroid
hormones and parathyroid hormones, applying this to alterations in the control process
(e.g., using thyroid hormones to treat obesity, Paget disease, etc.).
 Provide an overview of the thyroid and parathyroid gland. (Refer to PowerPoint
slide 2.)
 Discuss the action of the thyroid gland. (Refer to PowerPoint slide 3.)
 Discuss the thyroid control of hormone levels. (Refer to PowerPoint slide 4.)
 Discuss the functions of thyroid hormone. (Refer to PowerPoint slide 5.)
 Discuss how calcium is controlled in the body. (Refer to PowerPoint slide 6.)
 Discuss the types of thyroid dysfunction. (Refer to PowerPoint slide 7.)
 Discuss the causes of hypothyroidism. (Refer to PowerPoint slide 8.)
 Provide an overview of hyperthyroidism. (Refer to PowerPoint slide 9.)
 Provide an overview of parathyroid dysfunction. (Refer to PowerPoint slide 10.)
 Provide an overview of Paget’s disease. (Refer to PowerPoint slide 13.)
Learning Objective 2: Describe the therapeutic actions, indications, pharmacokinetics,
contraindications, most common adverse reactions, and important drug–drug interactions
associated with thyroid and parathyroid agents.
 Provide an overview of the thyroid hormones available for replacement of thyroid
hormone. (Refer to PowerPoint slide 14.)
 Discuss the action, indication, pharmacokinetics, contraindications, cautions,
adverse effects, and drug-to-drug interactions of thyroid hormone. (Refer to
PowerPoint slide(s) 15 to 17.)
 Discuss the action, indication, pharmacokinetics, contraindications, cautions,
adverse effects, and drug-to-drug interactions of antithyroid agents. (Refer to
PowerPoint slide(s) 18 to 20.)
 Discuss the action, indication, pharmacokinetics, contraindications, cautions,
adverse effects, and drug-to-drug interactions of iodine solutions. (Refer to
PowerPoint slide(s) 23 and 24.)
 Discuss the action, indication, pharmacokinetics, contraindications, cautions,
adverse effects, and drug-to-drug interactions of antihypocalcemic agents. (Refer
to PowerPoint slide(s) 25 and 26.)
 Provide an overview of antihypercalcemic agents. (Refer to PowerPoint slide
27.)
Learning Objective 3: Discuss the use of thyroid and parathyroid drugs across the
lifespan.
 Explain the use of thyroid and parathyroid drugs across the life span. (Refer to
PowerPoint slide 28.)
Learning Objective 4: Compare and contrast thyroid and parathyroid prototype drugs
with agents in their class.
 Discuss the thyroid hormone prototype drug Levothyroxin. (Refer to PowerPoint
slide 29.)
 Discuss the antithyroid agent prototype drug PTU. (Refer to PowerPoint slide
30.)
 Discuss the iodine solutions prototype drug strong iodine products. (Refer to
PowerPoint slide 31.)
 Discuss the antihypocalcemic agents prototype drug Calcitriol. (Refer to
PowerPoint slide 32.)
 Discuss the antihypercalcemic agents - bisphosphonates prototype drug
Alendronate. (Refer to PowerPoint slide 33.)
 Discuss the antihypercalcemic agents - calcitonins prototype drugs Calcitonin.
(Refer to PowerPoint slide 34.)
Learning Objective 5: Outline nursing considerations, including important teaching
points, for patients receiving drugs used to affect thyroid or parathyroid function.
 Discuss the nursing considerations for patients receiving thyroid hormone. (Refer
to PowerPoint slide 37 and Table on Nursing Considerations for Patients
Receiving Thyroid Hormone.)
 Discuss the nursing considerations for patients receiving antithyroid agents.
(Refer to PowerPoint slide 38 and Table on Nursing Considerations for
Patients Receiving Antithyroid Agents.)
 Discuss the nursing considerations for patients receiving antihypocalcemic agents.
(Refer to PowerPoint slide 39 and Table on Nursing Considerations for
Patients Receiving Antihypocalcemic Agents.)
 Discuss the nursing considerations for patients receiving antihypercalcemic
agents. (Refer to PowerPoint slide 40 and Table on Nursing Considerations for
Patients Receiving Antihypercalcemic Agents.)